Genome-wide Association Studies-GWAS
Polygenic Traits
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management
Human Genetics
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Sep 17, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Kaveh Hosseini1, Nazanin Anaraki1, Parham Dastjerdi1
1Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Artificial intelligence (AI) optimizes polygenic risk scores (PRS) for better cardiovascular disease prediction. AI-optimized PRS enhance accuracy, improving patient risk stratification and personalized prevention strategies.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: